Lederman S, Ottery FD, Cano A, Santoro N, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
PMID: 36924778